Cytochrome P450 enzymes and drug metabolism - Basic concepts and methods of assessment

被引:51
作者
Glue, P
Clement, RP
机构
[1] Schering Plough Corp, Res Inst, Dept Clin Pharmacol, Kenilworth, NJ 07033 USA
[2] Schering Plough Corp, Res Inst, Dept Drug Metab, Kenilworth, NJ 07033 USA
关键词
cytochrome P450; enzyme inhibition; enzyme induction; pharmacokinetics; drug interaction; in vitro assessment; clinical assessment;
D O I
10.1023/A:1006993631057
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
1. The cytochrome P450 enzyme family is one of the major drug metabolizing systems in man. 2. Factors such as age, gender, race, environment, and drug treatment may have considerable influence on the activity of these enzymes. 3. There are now well-established in vitro techniques for assessing the role of specific cytochrome P450 enzymes in the metabolism of drugs, as well as the inhibitory or inducing effects of drugs on enzyme activity. In vitro data have been utilized to predict clinical outcomes (i.e., pharmacokinetic interactions), with close correlations between in vitro and in vivo data. 4. This information can be of considerable practical assistance to clinicians, to help with rational prescribing or to prevent or minimize the potential for drug interactions.
引用
收藏
页码:309 / 323
页数:15
相关论文
共 80 条
[1]   PREVALENCE OF CYP2D6 GENE DUPLICATION AND ITS REPERCUSSION ON THE OXIDATIVE PHENOTYPE IN A WHITE-POPULATION [J].
AGUNDEZ, JAG ;
LEDESMA, MC ;
LADERO, JM ;
BENITEZ, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (03) :265-269
[2]   THE INFLUENCES OF DOSE AND ETHNIC-ORIGINS ON THE PHARMACOKINETICS OF NIFEDIPINE [J].
AHSAN, CH ;
RENWICK, AG ;
WALLER, DG ;
CHALLENOR, VF ;
GEORGE, CF ;
AMANULLAH, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (03) :329-338
[3]   GRAPEFRUIT JUICE AND DRUGS - HOW SIGNIFICANT IS THE INTERACTION [J].
BAILEY, DG ;
ARNOLD, JMO ;
SPENCE, JD .
CLINICAL PHARMACOKINETICS, 1994, 26 (02) :91-98
[4]  
BALANTGORGIA AE, 1989, THER DRUG MONIT, V11, P415
[5]   ENZYME-INDUCTION AND INHIBITION [J].
BARRY, M ;
FEELY, J .
PHARMACOLOGY & THERAPEUTICS, 1990, 48 (01) :71-94
[6]  
BENITEZ J, 1994, CLIN PHARMACOL THER, V55, P170
[7]   EXTREMELY RAPID HYDROXYLATION OF DEBRISOQUINE - A CASE-REPORT WITH IMPLICATION FOR TREATMENT WITH NORTRIPTYLINE AND OTHER TRICYCLIC ANTIDEPRESSANTS [J].
BERTILSSON, L ;
ABERGWISTEDT, A ;
GUSTAFSSON, LL ;
NORDIN, C .
THERAPEUTIC DRUG MONITORING, 1985, 7 (04) :478-480
[8]  
BERTILSSON L, 1981, LANCET, V1, P560
[9]   MOLECULAR-BASIS FOR RATIONAL MEGAPRESCRIBING IN ULTRARAPID HYDROXYLATORS OF DEBRISOQUINE [J].
BERTILSSON, L ;
DAHL, ML ;
SJOQVIST, F ;
ABERGWISTEDT, A ;
HUMBLE, M ;
JOHANSSON, I ;
LUNDQVIST, E ;
INGELMANSUNDBERG, M .
LANCET, 1993, 341 (8836) :63-63
[10]   PRONOUNCED DIFFERENCES BETWEEN NATIVE CHINESE AND SWEDISH POPULATIONS IN THE POLYMORPHIC HYDROXYLATIONS OF DEBRISOQUIN AND S-MEPHENYTOIN [J].
BERTILSSON, L ;
LOU, YQ ;
DU, YL ;
LIU, Y ;
KUANG, TY ;
LIAO, XM ;
WANG, KY ;
REVIRIEGO, J ;
ISELIUS, L ;
SJOQVIST, F .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (04) :388-397